Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes.

Aims: Patients with prostate cancer (PC) have a higher rate of non-cancer mortality than cancer-related, which could be partially attributed to the treatment they receive. We aimed to evaluate the effect of metformin addition to androgen deprivation therapy (ADT) among cancer prostate patients with type 2 DM.

Methodology: This prospective, two-arm study included 95 PC patients with type 2 DM who had ADT.